entitled Methionine from France:
Investigation No. 731–TA–1534 (Final).
By order of the Commission.
Issued: June 30, 2021.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2021–14428 Filed 7–6–21; 8:45 am]
BILLING CODE 7020–02–P

INTERNATIONAL TRADE COMMISSION

[Investigation Nos. 701–TA–473 and 731–TA–1173 (Second Review)]

Potassium Phosphate Salts From China

Determination

On the basis of the record developed in the subject five-year reviews, the United States International Trade Commission ("Commission") determines, pursuant to the Tariff Act of 1930 ("the Act"), that revocation of the antidumping duty order on potassium phosphate salts from China would be likely to lead to continuation or recurrence of material injury to U.S. industries producing dipotassium phosphate and tetrapotassium pyrophosphate within a reasonably foreseeable time.

Background

The Commission instituted these reviews on November 2, 2020 (85 FR 69352, November 2, 2020) and determined on February 5, 2021 that it would conduct expedited reviews (86 FR 29288, June 1, 2021).

The Commission made these determinations pursuant to section 751(c) of the Act (19 U.S.C. 1675(c)). It completed and filed its determinations in these reviews on June 30, 2021. The views of the Commission are contained in USITC Publication 5208 (June 2021), entitled Potassium Phosphate Salts China: Inv. Nos. 701–TA–473 and 731–TA–1173 (Second Review).

By order of the Commission.
Issued: June 30, 2021.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2021–14428 Filed 7–6–21; 8:45 am]
BILLING CODE 7020–02–P

---

NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

[Notice: 21–044]

Name of Information Collection:
Generic Clearance for the NASA Office of STEM Engagement Performance Measurement and Evaluation (Testing)

AGENCY: National Aeronautics and Space Administration (NASA).
ACTION: Notice of information collection.

SUMMARY: The National Aeronautics and Space Administration, as part of its ongoing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections.

DATES: Comments are due by August 6, 2021.

ADDRESSES: Written comments and recommendations for this information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/PRAMain. Find this information collection by selecting "Currently under 30-day Review—Open for Public Comments" or by using the search function.

FOR FURTHER INFORMATION CONTACT:
Requests for additional information or copies of the information collection instrument(s) and instructions should be directed to Claire Little, NASA Clearance Officer, NASA Headquarters, 300 E Street SW, JF0000, Washington, DC 20546, 202–358–2375 or email claire.a.little@nasa.gov.

SUPPLEMENTARY INFORMATION:

I. Abstract:
NASA’s founding legislation, the Space Act of 1958, as amended, directs the agency to expand human knowledge of Earth and space phenomena and to preserve the role of the United States as a leader in aeronautics, space science, and technology. The NASA Office of STEM Engagement administers the agency’s national education activities in support of the Space Act, including the performance measurement and evaluation of educational projects and programs. This generic clearance will allow the NASA Office of STEM Engagement to continue to test and pilot with subject matter experts, secondary students, higher education students, educators, and interested parties new and existing information collection forms and assessment instruments for the purposes of improvement and establishing validity and reliability characteristics of the forms and instruments. Existing information collections include the NASA Intern Survey (Retrospective Survey), NASA Internship Applicants and Awardees Survey (Retrospective Survey), STEM Challenges Impact Surveys (Educator Feedback Retrospective Survey), STEM Challenges Impact Surveys (Parent Survey), and STEM Challenges Impact Surveys (Student Retrospective Survey). Forms and instruments to be tested include program application forms, customer satisfaction questionnaires, focus group protocols, and project activity survey instruments. Methodological testing will include focus group discussions, pilot surveys to test new individual question items as well as the complete form and instrument. In addition, test-retest and similar protocols will be used to determine reliability characteristics of the forms and instruments. Methodological testing will assure that forms and instruments are accurately and consistently collect and measure what they are intended to measure and that data collection items are interpreted precisely and consistently, all towards the goal of accurate Agency reporting while improving the execution of NASA STEM Engagement activities.

II. Method of Collection: Electronic, paper, and focus group interviews.

III. Data
Title: Generic Clearance for the NASA Office of Education Performance Measurement and Evaluation (Testing).

OMB Number: 2700–0159.
Type of Review: Renewal of an existing collection.
Affected Public: Individuals and Households.
Estimated Annual Number of Activities: 8.
Estimated Number of Respondents per Activity: 2,800.
Annual Responses: 1.
Estimated Time per Response: 15 minutes.
Estimated Total Annual Burden Hours: 5,600.
Estimated Total Annual Cost: $54,082.

IV. Request for Comments: Comments are invited on: (1) Whether the proposed collection of information is necessary for the proper performance of the functions of NASA, including whether the information collected has practical utility; (2) the accuracy of NASA’s estimate of the burden (including hours and cost) of the proposed collection of information; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including automated collection techniques or the use of other forms of information technology.

---

* The record is defined in § 207.2(f) of the Commission’s Rules of Practice and Procedure (19 CFR 207.2(f)).
EXECUTIVE OFFICE OF THE PRESIDENT
Office of National Drug Control Policy

Application of Equity in U.S. National Drug Control Policy

AGENCY: Office of National Drug Control Policy.

ACTION: Request for information.

SUMMARY: The Office of National Drug Control Policy (ONDCP) is seeking comments from the public on whether and to what extent ONDCP’s policy development process, drug budget review and certification processes of the 18 National Drug Control Program Agencies, and Grant Administration Programs perpetuate systemic barriers to opportunities for underserved communities and individuals from those communities. ONDCP is also seeking comments from the public regarding how its future proposed policies, budgets, regulations, grants, or programs might be more effective in advancing equity.

DATES: ONDCP encourages and will accept public comments on or before August 6, 2021.

ADDRESSES: Written comments may be submitted by members of the general public and stakeholder organizations by email to OGC@ondcp.eop.gov.

SUPPLEMENTARY INFORMATION: ONDCP seeks input according to the processes outlined by Executive Order (E.O.) 13985, that requires agencies to select certain agency programs and policies and assess whether underserved communities and their members, face systemic barriers in accessing benefits and opportunities available pursuant to those policies and programs.

E.O. 13985 defines “equity” as the consistent and systematic fair, just, and impartial treatment of all individuals, including individuals who belong to underserved communities that have been denied such treatment, such as Black, Latino, and Indigenous and Native American persons, Asian Americans and Pacific Islanders and other persons of color; members of religious minorities; lesbian, gay, bisexual, transgender, and queer (LGBTQ+) persons; persons with disabilities; persons who live in rural areas; and persons otherwise adversely affected by persistent poverty or inequality. It defines “underserved communities” as populations sharing a particular characteristic, as well as geographic communities, that have been systematically denied a full opportunity to participate in aspects of economic, social, and civic life, as exemplified by the list in the preceding definition of “equity.”

The E.O. requires agencies to assess whether and to what extent, its programs and policies perpetuate systemic barriers to opportunities and benefits for people of color and other underserved groups. Such assessments will better equip agencies to develop policies and programs that deliver resources and benefits equitably to all. The E.O. also requires agencies to study strategies for allocating Federal resources, consistent with applicable law, in a manner that increases investment in underserved communities, and individuals from those communities, to address the historic failure to ensure investments are sufficient, just, and equal. However, many Federal datasets are not disaggregated by race, ethnicity, gender, disability, income, veteran status, or other key demographic variables. Furthermore, in carrying out the E.O., agencies shall consult with members of communities that have been historically underestimated in the Federal Government and underserved by, or subject to discrimination in, Federal policies and programs. The head of each agency shall evaluate opportunities, consistent with applicable law, to increase coordination, communication, and engagement with community-based organizations and civil rights organizations.

ONDCP is the agency in the Executive Office of the President primarily responsible for leading and coordinating the nation’s drug control policy through the development and oversight of the National Drug Control Strategy and the National Drug Control Budget. ONDCP recently released the Biden-Harris Administration’s Drug Policy Priorities for the Administration’s first year. The seven priorities propose specific and targeted actions to reduce overdoses and promote recovery, including advancing racial equity in our approach to drug policy, expanding access to quality treatment, reducing the supply of illicit substances and enhancing evidence-based harm reduction services that engage and build trust with people who use drugs, among others. The priorities emphasize several cross-cutting facets of the overdose epidemic, namely by advancing racial equity in drug policy and promoting harm-reduction efforts.

While ONDCP employs experts in policy, public health, and public safety, the agency also organizes formal consultations with key external stakeholders. These external perspectives are crucial to help develop national drug control policy. ONDCP seeks to incorporate more perspectives from a wide array of backgrounds, including those most impacted by United States’ drug policies.

Through budget review and certification processes, ONDCP aligns funding resources for 18 Federal government agencies and departments with the National Drug Control Strategy. The President’s Fiscal Year (FY) 2022 budget request, included a $41.0 billion investment for national drug program agencies, representing a $669.9 million increase over the FY 2021 enacted level. The largest increases in funding are for critical public health interventions like treatment and prevention services. Each spring, ONDCP’s policy and budget staff develop and share budget guidance letters with these agencies. Agencies then review the budget guidance letters and submit preliminary budget proposals to ONDCP. ONDCP reviews the budget proposals to ensure they meet the guidance requirements and, based on the outcome of the review, certifies agency budgets. Key information about where drug budget investments are directed and the impact for different demographic groups (e.g., by race, ethnicity, gender, disability, income, veteran status, and more) is not fully known.

Request for Comments: Pursuant to E.O. 13985, ONDCP is issuing this request for information (RFI), to gather data on whether and to what extent ONDCP’s policy development process, drug budget review and certification processes, and Grant Administration Programs perpetuate systemic barriers to opportunities for underserved communities and individuals from those communities. In addition, ONDCP is issuing this RFI to gather information as to how its future proposed policies, budgets, regulations, grants, or programs might be more effective in advancing equity. Public input, information, and recommendations will help ONDCP develop an approach to advance equity in drug policy.

The work of advancing equity requires a holistic assessment of ONDCP practices and policies. The agency welcomes submissions that provide resources, tools, and examples of how